Novartis' Cosentyx racks up more long-term data in psoriatic arthritis and ankylosing spondylitis
admin 15th June 2017 Uncategorised 0The ankylosing spondylitis and psoriatic arthritis markets are growing increasingly crowded, but Novartis now has something not all its rivals can boast: long-term data for its IL-17 med, Cosentyx.
More: Novartis' Cosentyx racks up more long-term data in psoriatic arthritis and ankylosing spondylitis
Source: fierce